BACKGROUND: ABO blood type locus has been reported to be an important genetic determinant of venous and arterial thrombosis in genome-wide association studies. We tested the hypothesis that ABO blood type alone and in combination with mutations in factor V Leiden R506Q and prothrombin G20210A is associated with the risk of venous thromboembolism and myocardial infarction in the general population. METHODS: We used data from 2 Danish studies that followed members of the general public from 1977 through 2010. We obtained the genotype of 66 001 white participants for ABO blood type, factor V Leiden R506Q and prothrombin G20210A. We calculated hazard ratios (HRs) and population attributable risk. Our main outcome measures were venous thromboembolism and myocardial infarction. RESULTS: The multivariable adjusted HR for venous thromboembolism was 1.4 (95% confidence interval [CI] 1.3-1.5) for non-O blood type (v. O blood type). For the factor V Leiden R506Q mutation, the adjusted HR was 2.2 (95% CI 2.0-2.5) for heterozygous participants and 7.0 (95%CI 4.8-10) for homozygous participants (v. participants without the mutation). For prothrombin G20210A, the adjusted HR was 1.5 (95%CI 1.2-1.9) for heterozygous participants and 11 (95% CI 2.8-44) for homozygous participants (v. participants without the mutation). When we combined ABO blood type and factor V Leiden R506Q or prothrombin G20210A genotype, there was a stepwise increase in the risk of venous thromboembolism (trend, p<0.001). The population attributable risk of venous thromboembolism was 20% for ABO blood type, 10% for factor V Leiden R506Q and 1% for prothrombin G20210A. Multivariable adjusted HRs for myocardial infarction by genotypes did not differ from 1.0. INTERPRETATION: ABO blood type had an additive effect on the risk of venous thromboembolism when combined with factor V Leiden R506Q and prothrombin G20210A mutations; blood type was the most important risk factor for venous thromboembolism in the general population.
BACKGROUND:ABO blood type locus has been reported to be an important genetic determinant of venous and arterial thrombosis in genome-wide association studies. We tested the hypothesis that ABO blood type alone and in combination with mutations in factor V LeidenR506Q and prothrombinG20210A is associated with the risk of venous thromboembolism and myocardial infarction in the general population. METHODS: We used data from 2 Danish studies that followed members of the general public from 1977 through 2010. We obtained the genotype of 66 001 white participants for ABO blood type, factor V LeidenR506Q and prothrombinG20210A. We calculated hazard ratios (HRs) and population attributable risk. Our main outcome measures were venous thromboembolism and myocardial infarction. RESULTS: The multivariable adjusted HR for venous thromboembolism was 1.4 (95% confidence interval [CI] 1.3-1.5) for non-O blood type (v. O blood type). For the factor V LeidenR506Q mutation, the adjusted HR was 2.2 (95% CI 2.0-2.5) for heterozygous participants and 7.0 (95%CI 4.8-10) for homozygous participants (v. participants without the mutation). For prothrombinG20210A, the adjusted HR was 1.5 (95%CI 1.2-1.9) for heterozygous participants and 11 (95% CI 2.8-44) for homozygous participants (v. participants without the mutation). When we combined ABO blood type and factor V LeidenR506Q or prothrombinG20210A genotype, there was a stepwise increase in the risk of venous thromboembolism (trend, p<0.001). The population attributable risk of venous thromboembolism was 20% for ABO blood type, 10% for factor V LeidenR506Q and 1% for prothrombinG20210A. Multivariable adjusted HRs for myocardial infarction by genotypes did not differ from 1.0. INTERPRETATION:ABO blood type had an additive effect on the risk of venous thromboembolism when combined with factor V LeidenR506Q and prothrombinG20210A mutations; blood type was the most important risk factor for venous thromboembolism in the general population.
Authors: A Y Nossent; V VAN Marion; N H VAN Tilburg; F R Rosendaal; R M Bertina; J A VAN Mourik; H C J Eikenboom Journal: J Thromb Haemost Date: 2006-10-16 Impact factor: 5.824
Authors: Zheng Ye; Eugene H C Liu; Julian P T Higgins; Bernard D Keavney; Gordon D O Lowe; Rory Collins; John Danesh Journal: Lancet Date: 2006-02-25 Impact factor: 79.321
Authors: R F Franco; M D Trip; H ten Cate; A van den Ende; M H Prins; J J Kastelein; P H Reitsma Journal: Br J Haematol Date: 1999-01 Impact factor: 6.998
Authors: P M Ridker; C H Hennekens; K Lindpaintner; M J Stampfer; P R Eisenberg; J P Miletich Journal: N Engl J Med Date: 1995-04-06 Impact factor: 91.245
Authors: M Shima; Y Fujimura; T Nishiyama; T Tsujiuchi; N Narita; T Matsui; K Titani; M Katayama; F Yamamoto; A Yoshioka Journal: Vox Sang Date: 1995 Impact factor: 2.144
Authors: A R Folsom; W Tang; N S Roetker; A V Kshirsagar; V K Derebail; P L Lutsey; R Naik; J S Pankow; M L Grove; S Basu; N S Key; M Cushman Journal: J Thromb Haemost Date: 2014-12-11 Impact factor: 5.824
Authors: Olga V Gran; Erin N Smith; Sigrid K Brækkan; Hilde Jensvoll; Terry Solomon; Kristian Hindberg; Tom Wilsgaard; Frits R Rosendaal; Kelly A Frazer; John-Bjarne Hansen Journal: Haematologica Date: 2016-06-16 Impact factor: 9.941
Authors: M Di Nisio; A Ponzano; G M Tiboni; M D Guglielmi; A W S Rutjes; E Porreca Journal: J Assist Reprod Genet Date: 2018-04-20 Impact factor: 3.412
Authors: Nicholas B Larson; Elizabeth J Bell; Paul A Decker; Mindy Pike; Christina L Wassel; Michael Y Tsai; James S Pankow; Weihong Tang; Naomi Q Hanson; Kristine Alexander; Neil A Zakai; Mary Cushman; Suzette J Bielinski Journal: Atherosclerosis Date: 2016-06-07 Impact factor: 5.162
Authors: Nicholas B Larson; Paul A Decker; Christina L Wassel; James S Pankow; Weihong Tang; Naomi Q Hanson; Michael Y Tsai; Suzette J Bielinski Journal: Hum Genet Date: 2016-02-16 Impact factor: 4.132